@article{c861ef1b5ba14f18be274c4166953e99,
title = "18F-Labeled Radiotracers for Prostate-specific Membrane Antigen: Historical Perspective and Future Directions",
keywords = "Prostate, Prostate-specific membrane antigen, Radiofluorinated, Radiofluorine",
author = "Rowe, {Steven P.} and Ali Salavati and Werner, {Rudolf A.} and Pienta, {Kenneth J.} and Gorin, {Michael A.} and Pomper, {Martin G.} and Solnes, {Lilja B.}",
note = "Funding Information: M.G. Pomper is coinventor on a US patent covering 18F-DCFPyL and, as such, is entitled to a portion of any licensing fees and royalties generated by this technology (this arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies). S.P. Rowe, K.J. Pienta, M.A. Gorin, and M.G. Pomper have received research funding from Progenics Pharmaceuticals, Inc., a wholly owned subsidiary of Lantheus Pharmaceuticals, Inc. the licensee of 18F-DCFPyL. S.P. Rowe and M.A. Gorin are consultants for, and on the speakers bureau of, Lantheus Pharmaceuticals, Inc. M.A. Gorin is a consultant for Blue Earth Diagnostics, Inc. S.P. Rowe is a consultant for Novartis.",
year = "2022",
month = oct,
doi = "10.1016/j.cpet.2022.07.003",
language = "English (US)",
volume = "17",
pages = "585--593",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "4",
}